Generic Drug Debates

March 5, 2012

March 6, 2012 | A feature of Obama's health care plan was cheaper generic drug options, but that's proving easier said than done. Approving biosimilars is a complex and drawn-out process, and an "interchangable" classification is still under debate. FDA will hold a hearing on May 11 to review the label. The discount percentage is also unclear, with numbers ranging from 10% to 90% off branded products. Huffington Post